Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Change In Receivables : ¥0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co Change In Receivables?

Suzhou Zelgen Biopharmaceuticals Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0.0 Mil. It means Suzhou Zelgen Biopharmaceuticals Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Suzhou Zelgen Biopharmaceuticals Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥-38.4 Mil. It means Suzhou Zelgen Biopharmaceuticals Co's Accounts Receivable increased by ¥38.4 Mil from Dec. 2022 to Dec. 2023 .

Suzhou Zelgen Biopharmaceuticals Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥112.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Suzhou Zelgen Biopharmaceuticals Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 94.44.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Suzhou Zelgen Biopharmaceuticals Co's liquidation value for the three months ended in Mar. 2024 was ¥1,060.1 Mil.

Suzhou Zelgen Biopharmaceuticals Co Change In Receivables Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co Change In Receivables Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-11.01

-20.87

-84.19

-17.41

-38.35

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Suzhou Zelgen Biopharmaceuticals Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.0 Mil.

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Suzhou Zelgen Biopharmaceuticals Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	112.023	/	108.244	*	91
=	94.44

2. In Ben Graham's calculation of liquidation value, Suzhou Zelgen Biopharmaceuticals Co's accounts receivable are only considered to be worth 75% of book value:

Suzhou Zelgen Biopharmaceuticals Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2414.896	-	1504.036	+	0.75 * 112.023	+	0.5 * 130.431
=	1,060.1

Suzhou Zelgen Biopharmaceuticals Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Suzhou Zelgen Biopharmaceuticals Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN

Website

http://www.zelgen.com

Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.

Executives

Zhang Bin	Core technical personnel
Huang Gang	senior management
Lv Bin Hua	Directors, senior managers, core technical personn
Lu Hui Ping	Directors, senior managers
Gao Qing Ping	senior management
Wu Ji Sheng	Directors, senior managers, core technical personn
Zhang Jun Li	senior management
Wu Li Qing	Core technical personnel
	Core technical personnel
Sheng Ze Lin	Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Headlines

No Headlines